Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Atour's 2026 Outlook: Asset-Light Expansion Scales Hotel Network to 2,175 Locations
2026-10-11 05:07 • The Motley Fool Positive Axe Cap view: Selective

Atour Lifestyle Holdings, a Chinese hospitality company, has achieved a Superscore of 79/100 from The Motley Fool's Hidden Gems system. The company combines hotel operations with high-margin retail sales and uses an asset-light manachise model to scale efficiently. Despite strong operational performance including 41% YoY revenue growth and 63% retail revenue surge in Q2 2026, the stock is down 6% over the past 12 months due to broader macroeconomic headwinds. Key concerns include concentrated founder voting power (69%), related-party transactions, and China-specific regulatory risks.

Axe note: Atour's asset-light expansion drives rapid hotel growth, but governance and China risks advise caution for South African investors.

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
2026-10-11 02:15 • The Motley Fool Positive Axe Cap view: Selective

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Axe note: Balancing yield and risk in big pharma stocks is essential—don’t chase high dividends without diversification.

Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
2026-10-11 00:37 • The Motley Fool Mixed Axe Cap view: Bearish

Cerebras Systems expects $880-890 million in core revenue for 2026, comparable to Nvidia's data center business revenue of $830 million in fiscal 2017. However, the similarities end there. Unlike Nvidia, which had a profitable gaming business funding its AI expansion, Cerebras is unprofitable with negative operating margins and relies on just three customers for three-quarters of revenue. The stock trades at 44x expected revenue and is valued at two-thirds of Nvidia's entire 2016 market cap, raising questions about whether it can replicate Nvidia's growth trajectory.

Axe note: Cerebras is growing fast but lacks Nvidia’s solid foundation and profitability, raising big questions for investors.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand